- Global Pharma News & Resources

Biotest AG: Biotest increases operating result by EUR 20 million in 2018

DGAP-News: Biotest AG / Key word(s): Annual Results

28.03.2019 / 09:00
The issuer is solely responsible for the content of this announcement.


Biotest increases operating result by EUR 20 million in 2018

- EBIT rises to EUR 10.6 million

- Sales grow by 5.9% to EUR 400.3 million

- Biotest meets sales and EBIT forecast

Dreieich, 28 March 2019. In financial year 2018, the Biotest Group generated sales of EUR 400.3 million from continuing operations, compared with EUR 378.1 million in the previous year. This corresponds to a 5.9% increase in sales. All sales regions recorded single-digit percentage sales growth rates in 2018.

EBIT from continuing operations amounted to EUR 10.6 million in financial year 2018. The previous year's EBIT in the amount of -9.3 million was burdened by the recall of a drug.

For the continuing operations of the Biotest Group, this resulted in earnings before taxes (EBT) of EUR -6.0 million after EUR -26.0 million in the same period in the previous year. EBT from discontinued operations amounted to EUR 194.6 million in 2018 due to the recognition of the gain on the disposal of the US plasmapherese centres, compared with EUR 12.9 million in the same period of the previous year.

Earnings after taxes from continuing operations amounted to EUR -12.9 million after EUR -16.4 million in 2017.

Earnings after taxes from discontinued operations rose to EUR 194.6 million from EUR 12.9 million in the previous year, mainly due to the recognition of the gain on the disposal of the US companies.

The Biotest Group's total earnings after tax (EAT) from continuing and discontinued operations amounted to EUR 181.7 million (previous year: EUR -3.5 million).

In financial year 2018, Biotest further expanded its network of the Group's own plasma collection centres in Europe. In this time, the Company opened two plasma collection centres in the Czech Republic and one more centre in Germany in 2019. Currently 20 collection centres in Europe ensure the long-term supply of plasma.

The important expansion project Biotest Next Level was further advanced in 2018. The first process system for purification of IgG Next Generation was successfully qualified in June 2018 and transferred to Biotest.

Outlook 2019:

For financial year 2019, the Board of Management expects sales growth in the mid-single-digit percentage range for continuing operations. Earnings in 2019 will be influenced by various factors. Besides the planned expenditures of EUR 80 to 90 million for the Biotest Next Level expansion project, including the associated research and development costs, the tense situation in the crisis regions, particularly in the Middle East, could also have an impact. Furthermore, a partner is being sought for advanced development projects. Based on the aforementioned factors, the Board of Management expects EBIT from continuing operations to be between EUR -5 million and EUR +5 million if partnering can be successfully concluded in 2019.

The annual report 2018 is available on the company's website at Also available for download from the website is the presentation for today's conference for analysts and journalists.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in certain cancer indications and in systemic lupus erythematodes, an autoimmune disease, which are produced by recombinant technologies. Biotest has more than 1,700 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
phone: +49-6103-801-4406

PR contact
Dirk Neumüller
phone: +49-6103-801-269

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany,

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

28.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 792645

End of News DGAP News Service

Editor Details

Last Updated: 28-Mar-2019